Granules India gets USFDA nod for muscle pain tablets
NEW DELHI: Granules India has received approval from the US health regulator for generic Methocarbamol tablets in two strengths used for the treatment of muscle spasms and pain.
The USFDA has approved the abbreviated new drug application (ANDA) for Methocarbamol tablets in the strengths of 500 mg and 750 mg, Granules India said in a filing to the BSE.
The product is the generic version of Auxilium Pharmaceuticals LLC’s Robaxin tablets in the same strength The company intends to commercialise the product shortly, the filing said.
Shares of Granules India were trading at Rs 100.05 per scrip on BSE, down 0.30 percent from the previous close
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd